TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change of Blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Insulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Triglyceride level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Radiographic criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of blood oxygenation level dependent (BOLD) signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot planter pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Treatment mean cumulative irritation score
Endpoint domain: Adverse events/effects
Primary endpoint: Door-to-Balloon Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NEPSY-II Neuropsychological Battery (change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wechsler Intelligence Scale for Children Fourth Edition (WISC-IV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local Ocular Tolerability (LOT) Visual Analogue Scale (VAS)
Endpoint domain: Adverse events/effects
Primary endpoint: Cataract Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Implicit motor learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capacity of the score to discriminate patients for palliative approach
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate after hernia surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of Neuropsychiatric Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in BOLD signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in breakpoint at PRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve of BUP/NLX With TPV/r
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leukocyte rolling in scleral blood vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hospital mortality to day 28
Endpoint domain: Mortality/survival
Primary endpoint: Global quality of images
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Outcome Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Early tumor recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Radiographic peri-implant marginal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Identification of acute febrile episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection of confirmed or probable dengue infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ventilatory threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of the oral challenge
Endpoint domain: Adverse events/effects
Primary endpoint: Risk factor for keratoconus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Microvascular permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Tests
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Clinically Relevant Vital Sign Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Worst Toxicity Grade Hematology Laboratory Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: emergency room process times
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: time to wean off vasopressor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of infants not meeting AAP sleeping environment recommendations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ICU and hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: Cases Without Aseptic Loosening, Intraoperative Femoral Fracture or Thigh Pain
Endpoint domain: Adverse events/effects
Primary endpoint: adherence measured by the number of sachets used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy of recovery of virus-specific immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correlation with protection from viral reactivation/disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Neurocognitive battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: changes in heart size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: level of hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Participant died during the observation period
Endpoint domain: Mortality/survival
Primary endpoint: Urine concentration of triptorelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak Oxygen Uptake (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of mechanical ventilation in hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mYPAS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Localization distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of the Gingival Index values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving and Maintaining Castrate Levels of Serum Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ischemia area percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the insulin aspart concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retinal arteriovenous ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in seated trough Diastolic Blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in walking security
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of recommendations' follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum Drug Concentration (Cmax) of LY3185643 and rGlucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve (AUC) of LY3185643 and rGlucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Maximum Concentration (Cmax) of Blood Glucose of LY3185643 and rGlucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ischemic stroke and peripheral embolism
Endpoint domain: Mortality/survival
Primary endpoint: Bleeding requiring hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate Per Composite Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective Response Rate Per RANO-BM Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With No Vomiting and No Retching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Volume reduction of the target leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with NAFLD and gestational diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of barriers to depression treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of facilitators of depression treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of preferences for depression treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sustained response post CPI suspension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of P-selection expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of PAC-1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of P2Y12 acceptor expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of PDE enzymes expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Aortic Pulse Wave Velocity (aPWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary urokinase receptor concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain intensity difference to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Pleurx Catheter or Paracentesis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of nutrition failure
Endpoint domain: Adverse events/effects
Primary endpoint: Laryngectomy-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Physical Examination Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinical Chemistry Parameters of PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Urinalysis Abnormalities by Dipstick Method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: greater reduction in depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Crisis Resource Management skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Reported Shoulder Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Concentration of nifedipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of treatments
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from admission 6-Minute Walk Test at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional scores according to Karlsson score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inappropriate Antibiotic Prescribing Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self-Efficacy in Performing SSE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite of bile leakage and iatrogenic duct injury
Endpoint domain: Adverse events/effects
Primary endpoint: Arterial Stiffness (Carotid Artery Compliance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delay in drug use initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substance use frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-violent delinquent behavior frequency
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Violent delinquent behavior frequency
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Delay in initiation of sexual activity
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Feeding disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse Events Experienced While on Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: peak bone mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disrupted microarchitecture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With One or More Injection-site Adverse Experiences Prompted on the Vaccination Report Card
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Elevated Oral Body Temperature (>=37.8° C, >=100° F)
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Crowding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attentional Blink
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: R0/R1 Resection Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Chedoke Arm and Hand Activity Inventory (CAHAI-9) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in electrophysiological muscle activity after nerve transfers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to symptomatic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Trypsin-like Enzyme Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of rotator cuff tendonitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Urinary sodium concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of mechanical and surgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients programmed to non-specific IBP settings
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in body image perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immunogenicity of the study vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to sit unsupported
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to eat and drink
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Parasite reduction rate 24 hours after onset of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of patients with no progressive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physical Activity (LTPAQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Accelerometer Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Technical Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathology-related information
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cmax of 14C Labelled Volasertib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Fraction of 14C-ratioactivity Excreted in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of Volasertib and CD10899 in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of USL255
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients requiring surgical dental care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of durable complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of score of the Brief Symptom Rating Scale (BSRS-5) for psychological distress level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of score in 9-item Concise Mental Health Checklist (CMHC-9) for suicide risk assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of score in Brief Resilience Coping Scale (BRCS) for tendencies to cope with stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geometric Mean of Antibody Titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in WOMAC OA Index pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WOMAC OA Index physical function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI-based evidence of structural heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EPS-based evidence of structural heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of self-reported depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rates of BMD testing and osteoporosis pharmacotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change of kinematic analyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of Fugl-Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Frozen Plasma Transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Anastomotic leak rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intravascular catheter position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intradialytic Clearance of Antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lumbopelvic kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fibroid volume measured on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibroid symptoms reported by participant
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Red blood cell count (hematocrit)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Poor Blood Flow Rate (BFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CPFS at 3y
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in cycloplegic refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of trametinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of trametinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Equilibrium scores of the Sensory Organization Test (SOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core Strength position 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Core Strength position 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum amplitude on thromboelastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in CK-MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in markers of oxidative stress and inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of overall disease control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of invasive cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification of tissue of cancer origin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Detectable Bone Marrow Testosterone Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Detectable Bone Marrow Dihydrotestosterone (DHT) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Difference in Bone Marrow Testosterone Levels Between Participants With and Without Serum Prostate Specific Antigen Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes